Ami J Shah

Dr. Ami J Shah

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MGM. Goodwin
M. Goodwin
ELE. Lee
E. Lee
ULU. Lakshmanan
U. Lakshmanan
SSS. Shipp
S. Shipp
LFL. Froessl
L. Froessl
RBR. Bacchetta
R. Bacchetta
Gene editing of FOXP3 ensures regulated expression and restored function in T cells, supporting clinical applicability.

1 June 2008 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
ASAmi J Shah
Ami J Shah
KEKaren Epport
Karen Epport
CAColleen Azen
Colleen Azen
RKRenna Killen
Renna Killen
KWKathy Wilson
Kathy Wilson
KWKenneth I. Weinberg
Kenneth I. Weinberg
Neurocognitive function of pediatric patients is of great concern after hematopoietic stem cell transplantation (HSCT). We evaluated the neurocognitive function of pediatric patients pre-HSCT, 1, 3, and 5 years post-HSCT. All patients had a hematologic malignancy and received therapy to their central nervous system. Healthy siblings were tested as a comparison group. Pediatric patients with a hematologic malignancy did not have a significant decrease in their cognitive function before HSCT compared with their siblings except in areas of academic achievement. Our study population had significant declines in visual motor skills and memory test scores within the first year post-HSCT. By 3 years post-HSCT, there was an improvement in the visual motor development scores and memory scores, but there were new deficits in verbal skills. By 5 years post-HSCT, there were progressive declines in verbal skills (P=0.005), performance skills (0.04), and new deficits seen in long-term verbal memory scores (0.04). On the basis of the raw scores, most of these tests showed that patients had an inability to acquire new skills at a rate comparable to their age-matched healthy peers. However, long-term memory scores showed definite declines. The greatest decline in neurocognitive function occurred in those patients who received cranial irradiation either as part of their initial therapy or as part of their HSCT conditioning. Pediatric patients who received HSCT for hematologic malignancies have neurocognitive deficiencies that are both acute and chronic. Although some patients have acute deficits that appear and improve over time, other patients have progressive declines in neurocognitive function that are chronic.

1 October 2005 in Pediatrics
Verified
Journal Article
Closed access
ASAmi J Shah
Ami J Shah
NKNeena Kapoor
Neena Kapoor
GCGay M. Crooks
Gay M. Crooks
RPRobertson Parkman
Robertson Parkman
KWKenneth I. Weinberg
Kenneth I. Weinberg
DKDonald Kohn
Donald Kohn
Histocompatible hematopoietic stem cell transplantation (HSCT) was conducted on a 4.5-year-old girl with Niemann-Pick disease type B. The donor was her unaffected brother. At the time of transplantation, she had severe pulmonary disease. After her first HSCT, she developed graft failure. Five years after her second HSCT, her sphingomyelinase levels are within normal levels, she has no pulmonary symptoms, and aside from persistent graft versus host disease, she is doing well.

1 February 2004 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
ASAmi J Shah
Ami J Shah
CLCarl Lenarsky
Carl Lenarsky
NKNeena Kapoor
Neena Kapoor
GCGay M. Crooks
Gay M. Crooks
DKDonald Kohn
Donald Kohn
KWKen Weinberg
Ken Weinberg
Bone marrow transplantation (BMT) has become the standard therapy for children with relapsed acute lymphoblastic leukemia. The authors report their experience with histocompatible BMT for 52 children with acute lymphoblastic leukemia conditioned with a non-total body irradiation (TBI) regimen using busulfan and cyclophosphamide (Bu/Cy). The efficacy and long-term toxicity of the Bu/Cy regimen were determined. Overall survival was 35%. One-year, 3-year, and 7-year event-free survival rates were 54%, 33%, and 23%, respectively. Of the 52 BMT recipients, 26 relapsed. Thirteen of the relapsed patients received a second BMT and three were surviving as of this writing. The most frequent cause of death was leukemia relapse. An initial remission duration of less than 18 months was a factor in decreasing the event-free survival. The Bu/Cy regimen was well tolerated, with minimal transplant-related mortality. Neurocognitive function was tested before BMT and 1 year after BMT. When 1-year posttransplant neurocognitive test scores were compared with pretransplant scores, there was no decrease. However, there was a significant decrease in the pretransplant neurocognitive test scores in BMT recipients compared with their normal siblings. The use of Bu/Cy as a conditioning regimen for BMT does not appear to affect posttransplant neurocognitive function. Other long-term side effects, such as endocrinopathies and secondary malignancies, were also minimal. These data show that the Bu/Cy regimen is well tolerated, but the overall survival rate remains low.

30 July 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
EBEmilie Pauline Buddingh
Emilie Pauline Buddingh
MSMary Slatter
Mary Slatter
JBJuan Carlos Aldave Becerra
Juan Carlos Aldave Becerra
LGLaura Alonso Garcia
Laura Alonso Garcia
EAErik von Asmuth
Erik von Asmuth
CSCatharina Schuetz
Catharina Schuetz
Germline gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) are associated with infections, including chronic mucocutaneous candidiasis and autoimmunity. Morbidity is high, and disease manifestations can be life-threatening. Curative allogeneic hematopoietic stem cell transplantation (HSCT) historically has had poor outcomes. We identified 36 patients with STAT1 GOF disease, receiving 40 HSCT procedures in 2010–2023, in a combined effort of the EBMT-IEWP and the PIDTC. Median age at first transplant was 11 years (range 1–33). Indications for HSCT were combined immunodeficiency, severe and/or refractory infections, and autoimmunity. Acute GvHD occurred in 22/40 HSCT procedures; 5 patients suffered from grade III/IV acute GvHD. One patient had chronic GvHD. Overall survival was 72.2%, and event-free survival was 55.6%, markedly improved from an earlier report on HSCT for STAT1 GOF disease. Patients with an HCT-CI score of 1 or higher had worse outcome. Pre-treatment with Janus kinase (JAK) inhibitors was associated with better event-free survival.